Several antigens, including GD2, PSMA, Muc1, and mesothelin, have been targeted in CAR‐T cell therapies for cervical cancer (ClinicalTrials.gov identifiers: NCT03356795 and NCT01583686). This evidence concerns the gene MSLN and cervical cancer.